ANI Pharmaceuticals, Inc.

NasdaqGM:ANIP Stok Raporu

Piyasa değeri: US$1.1b

ANI Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

ANI Pharmaceuticals CEO'su Nikhil Lalwani, Sep2020 tarihinde atandı, in görev süresi 4.17 yıldır. in toplam yıllık tazminatı $ 8.08M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.5% maaş ve 90.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.91% ine doğrudan sahiptir ve bu hisseler $ 21.28M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 4.2 yıldır.

Anahtar bilgiler

Nikhil Lalwani

İcra Kurulu Başkanı

US$8.1m

Toplam tazminat

CEO maaş yüzdesi9.5%
CEO görev süresi4.2yrs
CEO sahipliği1.9%
Yönetim ortalama görev süresi3yrs
Yönetim Kurulu ortalama görev süresi4.2yrs

Son yönetim güncellemeleri

Recent updates

Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly

Nov 09
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

Nov 02

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

Oct 11

There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

Sep 10
There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Aug 14
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

Aug 08
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10
Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17
These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15
Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Sep 22
Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Feb 22
Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

Oct 28
We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

ANI Pharma launches generic Prochlorperazine maleate tablets

Aug 29

ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval

Aug 16

CEO Tazminat Analizi

Nikhil Lalwani'un ücretlendirmesi ANI Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

US$24m

Mar 31 2024n/an/a

US$31m

Dec 31 2023US$8mUS$764k

US$15m

Sep 30 2023n/an/a

US$10m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$5mUS$737k

-US$50m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$65m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021US$7mUS$715k

-US$43m

Sep 30 2021n/an/a

-US$22m

Jun 30 2021n/an/a

-US$17m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$4mUS$199k

-US$23m

Tazminat ve Piyasa: Nikhil 'nin toplam tazminatı ($USD 8.08M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.17M ).

Tazminat ve Kazançlar: Nikhil şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Nikhil Lalwani (46 yo)

4.2yrs

Görev süresi

US$8,078,353

Tazminat

Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Nikhil Lalwani
President4.2yrsUS$8.08m1.91%
$ 21.3m
Stephen Carey
Senior VP of Finance & CFO8.5yrsUS$2.58m0.83%
$ 9.2m
Chad Gassert
Senior Vice President of Corporate Development & Strategy3yrsUS$1.90m1.24%
$ 13.8m
Christopher Mutz
Senior Vp & Head of Rare Disease3.8yrsUS$1.91m0.39%
$ 4.4m
Ori Gutwerg
Senior Vice President of Generics3.8yrsUS$1.94m0.40%
$ 4.4m
Muthusamy Shanmugam
Head of R&D3yrsVeri yok0.26%
$ 2.9m
James Marken
Senior Vice President of Operations8.5yrsUS$1.43m0.60%
$ 6.7m
Elizabeth Powell
Chief Compliance Officer & Head of Legal of Rare Disease2.8yrsVeri yokVeri yok
Meredith Cook
Senior VP2.3yrsVeri yok0.29%
$ 3.2m
Krista Davis
Senior VP & Chief Human Resources Officer2.2yrsVeri yok0.26%
$ 2.8m
Mary Pao
Chief Medical Officer2.8yrsVeri yokVeri yok
Thomas Rowland
Senior VP & Head of Established Brands3yrsVeri yok0.17%
$ 1.9m

3.0yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: ANIP 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Nikhil Lalwani
President4.2yrsUS$8.08m1.91%
$ 21.3m
Muthusamy Shanmugam
Head of R&D3yrsVeri yok0.26%
$ 2.9m
Patrick Walsh
Independent Chairman6.5yrsUS$422.21k0.38%
$ 4.3m
Antonio Pera
Independent Director4.3yrsUS$393.25k0.16%
$ 1.8m
Thomas Haughey
Independent Director6.5yrsUS$412.21k0.26%
$ 2.9m
Jeanne Thoma
Independent Director4.3yrsUS$395.75k0.21%
$ 2.3m
Renee Tannenbaum
Independent Director2.7yrsUS$392.37k0.12%
$ 1.3m
Matthew Leonard
Independent Director1.3yrsUS$470.76k0.061%
$ 682.5k

4.2yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ANIP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.2 yıldır).